VariZIG market seen expanding through 2035 on rising VZV risk and preventive care demand
The VariZIG market is forecast to grow as more immunocompromised patients, pregnant women and newborns need post-exposure protection against varicella-zoster virus. The Business Research Company says North America led the market in 2025, with growth supported by plasma collection, biologic safety screening and higher healthcare spending.
Why it matters: - VariZIG is used to reduce the severity of chickenpox after exposure in high-risk patients, making it a key preventive therapy for vulnerable groups. - The market outlook matters because rising varicella-zoster virus exposure, aging populations and immune suppression are increasing demand for post-exposure prophylaxis. - Higher healthcare spending can improve access to essential therapies like VariZIG and help limit severe complications from varicella-zoster virus infections.
What happened: - The Business Research Company published its VariZIG Market Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the VariZIG market is gaining traction as healthcare systems focus more on infection prevention. - North America was the largest regional market for VariZIG in 2025. - The coverage also includes Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.
The details: - VariZIG is a plasma-derived hyperimmune globulin rich in antibodies targeting varicella-zoster virus. - The treatment is given by intramuscular injection. - VariZIG provides passive immunity by supplying ready-made antibodies. - The therapy is primarily used after exposure to lessen chickenpox severity in immunocompromised patients, pregnant women and newborns. - VariZIG is most effective when given within 96 hours of exposure. - Historical market growth was supported by plasma fractionation technologies that enable hyperimmune globulin production. - Wider awareness of varicella complications helped drive acceptance of hospital-based prophylaxis protocols. - Regulatory approvals for hyperimmune globulins and an established immunization infrastructure also supported past market growth. - The report identifies rising demand for protection among immunocompromised patients as a major growth driver. - Increased attention to maternal and neonatal care is also supporting preventive use. - Expansion of plasma collection networks is improving raw material availability. - Advances in biologic safety screening are supporting safer products. - Rising investment in preventive immunotherapies is strengthening the market outlook. - Increasing incidence of varicella-zoster virus infections is fueling demand. - Varicella-zoster virus causes chickenpox during initial infection and can later reactivate as shingles, or herpes zoster. - Lower vaccination coverage, an aging population and immune suppression from medical treatments are linked to recent infection increases. - The Florida Department of Health reported 653 varicella cases in 2023, up from 428 in 2022. - UK healthcare spending rose 5.6% between 2022 and 2023, reaching about $317.63 billion (£292 billion) in 2023, according to the Office for National Statistics. - The report says stronger health budgets support procurement and distribution of VariZIG. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.
Between the lines: - The market story is less about a new drug category and more about widening clinical need for an established post-exposure therapy. - The strongest demand signals come from public health pressure points: more infections, more immunocompromised patients and more emphasis on preventive care. - The report’s regional detail suggests that market opportunity is broad, but the current center of gravity remains in North America.
What's next: - The report projects continued market expansion through 2035 as plasma supply, screening technology and preventive immunotherapy investment improve. - Demand should stay tied to exposure management in high-risk patients and to healthcare systems' ability to identify and treat them quickly. - The company offers a free sample of the report and the full market report.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
UK Post Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.